Delaware – May, 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of new therapeutics, recently secured an additional private investment of $50 000.
Company is pleased to confirm that it secured funding of $50,000 as a convertible loan from life sciences business angels. Under the agreement company will deploy proceeds to continue its business operational activities. Investing parties are individuals engaged into health and new therapeutics businesses.
Pawel Zolnierczyk, Chief Executive Officer:
We are delighted that our individuals from our sector have decided to invest into iQure Pharma. This is great and represent high level of trust into company and its prospect. Secured funding will be important and will allow Company to co-invest with prospective investors into our Neuropathic Pain portfolio. iQure Pharma is looking to continue its efforts to secure portfolio of promising therapeutics and funding required to progress with its development.